Biomarkers predicting Alzheimer's disease in cognitively normal aging

Yong S. Shim, John C. Morris

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


The pathophysiologic process of Alzheimer's disease (AD) begins years before the diagnosis of clinical dementia. This concept of preclinical AD has arisen from the observation of AD pathologic findings such as senile plaques and neurofibrillary tangles in the brains of people who at the time of death had normal cognitive function. Recent advances in biomarker studies now provide the ability to detect the pathologic changes of AD, which are antecedent to symptoms of the illness, in cognitively normal individuals. Functional and structural brain alterations that begin with amyloid-β accumulation already show the patterns of abnormality seen in individuals with dementia due to AD. The presence of preclinical AD provides a critical opportunity for potential interventions with disease-modifying therapy. This review focuses on the studies of antecedent biomarkers for preclinical AD.

Original languageEnglish
Pages (from-to)60-68
Number of pages9
JournalJournal of Clinical Neurology (Korea)
Issue number2
StatePublished - Jun 2011


  • Alzheimer's disease
  • Biomarker
  • Preclinical


Dive into the research topics of 'Biomarkers predicting Alzheimer's disease in cognitively normal aging'. Together they form a unique fingerprint.

Cite this